PYLERA
Drug
Allergan Inc.
Total Payments
$121,393
Transactions
4
Doctors
1
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $60,211 | 1 | 0 |
| 2018 | $61,166 | 2 | 0 |
| 2017 | $15.80 | 1 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $121,377 | 3 | 100.0% |
| Education | $15.80 | 1 | 0.0% |
Payments by Type
Research
$121,377
3 transactions
General
$15.80
1 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| EFFICACY OF PANCREATIC ENZYME SUPPLEMENTATION FOR SYMPTOM CONTROL IN CELIAC DISEASE NOT RESPONDING TO THE GLUTEN FREE DIET | Allergan Inc. | $121,377 | 0 |
Top Doctors Receiving Payments for PYLERA
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Boston, MA | $121,377 | 3 |
| , MD | Gastroenterology | Asheboro, NC | $15.80 | 1 |
Ad
Manufacturing Companies
- Allergan Inc. $121,393
Product Information
- Type Drug
- Total Payments $121,393
- Total Doctors 1
- Transactions 4
About PYLERA
PYLERA is a drug associated with $121,393 in payments to 1 healthcare providers, recorded across 4 transactions in the CMS Open Payments database. The primary manufacturer is Allergan Inc..
Payment data is available from 2017 to 2019. In 2019, $60,211 was paid across 1 transactions to 0 doctors.
The most common payment nature for PYLERA is "Unspecified" ($121,377, 100.0% of total).
PYLERA is associated with 1 research study, including "EFFICACY OF PANCREATIC ENZYME SUPPLEMENTATION FOR SYMPTOM CONTROL IN CELIAC DISEASE NOT RESPONDING TO THE GLUTEN FREE DIET" ($121,377).